atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
30 Giugno 2022 - 12:59PM
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad
Beyer as Chief Executive Officer
Kures Therapeutics, Inc (“Kures”), an atai Life Sciences N.V.
(Nasdaq: ATAI) (“atai”) company focused on developing treatment
options to better manage addictions, depression, and pain, today
announced the appointment of Chad E. Beyer, Ph.D., MBA, currently
Senior Vice President of Research and Development at Promentis
Pharmaceuticals, Inc (“Promentis”), as Chief Executive Officer of
Kures, effective July 1, 2022.
Dr. Beyer has over 25 years of experience in the discovery,
research and translational development of medications that treat
the central nervous system and neurological disorders. He has led
several preclinical and clinical drug discovery teams and
participated in the submission of more than 30 INDs and provided
supporting data for the commercialization and life-cycle management
of two blockbuster medications. Dr. Beyer has authored more than 70
manuscripts and co-edited the book entitled “Next Generation
Antidepressants” and co-founded the journal “Technology Transfer
& Entrepreneurship.”
“Dr. Beyer has dedicated his career to advancing CNS treatments
– and this dedication exemplifies our mission here at atai,” said
atai Co-Founder and Chief Scientific Officer and outgoing Kures
CEO, Srinivas Rao. “I can’t think of a better person to lead the
Kures team into the next phase of its journey than Dr. Beyer, and I
look forward to seeing what we can achieve together.”
Outgoing Kures CEO Dr. Srinivas Rao will continue to support and
advise Kures’ programs from his role at atai Life Sciences.
About Kures TherapeuticsKures is
developing KUR-101 for the treatment of
OUD. KUR-101 is a deuterated version of mitragynine, the
major alkaloid in kratom that is a
relatively low-potency mu-opioid receptor, or MOR,
agonist. KUR-101 is a semisynthetically produced drug
substance designed to improve the safety profile and potential
effectiveness of mitragynine. In results from our preclinical
studies carried out to date, KUR-101 has shown
dose-dependent analgesic effect without inducing significant
respiratory depression at therapeutic doses in animal models.
About atai Life Sciences atai Life
Sciences is a clinical-stage biopharmaceutical company aiming to
transform the treatment of mental health disorders. Founded in 2018
as a response to the significant unmet need and lack of innovation
in the mental health treatment landscape, atai is dedicated to
acquiring, incubating, and efficiently developing innovative
therapeutics to treat depression, anxiety, addiction, and other
mental health disorders.
atai's business model combines funding, technology, scientific,
and regulatory expertise with a focus on innovative compounds,
including psychedelic therapy and other drugs with differentiated
safety profiles and therapeutic potential. By pooling resources and
best practices, atai aims to responsibly accelerate the development
of new medicines across its companies to achieve clinically
meaningful and sustained behavioral change in mental health
patients.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. For more
information, please visit www.atai.life.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any express or
implied statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements, including without limitation, statements about our
expectations relating to management transition changes and related
timelines, statements regarding Kures (KUR-101), including the
therapeutic potential of KUR-101, and similar statements of a
future or forward-looking nature. Forward-looking statements are
neither promises nor guarantees, but involve known and unknown
risks and uncertainties that could cause actual results to differ
materially from those projected, including, without limitation, the
important factors discussed under the caption “Risk Factors” in
atai's most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission (“SEC”), as updated by atai’s
subsequent filings with the SEC.
Any forward-looking statements made herein speak only as of the
date of this press release, and you should not rely on
forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
the future results, performance, or achievements reflected in the
forward-looking statements will be achieved or will occur. Except
as required by applicable law, we undertake no obligation to update
any of these forward-looking statements for any reason after the
date of this press release or to conform these statements to actual
results or revised expectations.
Investor Contact
Greg WeaverChief Financial OfficerGreg.Weaver@atai.life
Media Contact
Allan MalievskySenior Director, External
Affairsallan@atai.life
Grafico Azioni ATAI Life Sciences NV (TG:9VC)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni ATAI Life Sciences NV (TG:9VC)
Storico
Da Mar 2023 a Mar 2024